A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Clinical trial NCT02677922 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02677922
- Sponsor
- Celgene
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-03
- Primary completion
- 2018-08-02
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.